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In developed countries, humans are potentially
exposed to a wide range of chemicals present
in commonly used products. For the most
part, no information exists about the extent of
the human exposure to these chemicals, and
the potential toxic effects of these compounds
are largely unknown. Bisphenol A (2,2´-bis[4-
hydroxyphenyl]propane; BPA) and alkyl-
phenols (APs) are among these chemicals. BPA
is used to manufacture polycarbonate plastic
and epoxy resins, which are used in baby bot-
tles, as protective coatings on food containers,
and for composites and sealants in dentistry
(Arenholt-Bindslev et al. 1999; Howe et al.
1998; Sajiki and Yonekubo 2003). APs are
used to make alkylphenol ethoxylates (APEs),
widely used nonionic surfactants. APEs are
applied as emulsifying, wetting, dispersing, or
stabilizing agents in numerous industrial, agri-
cultural, and domestic consumer products
including detergents and pesticide formula-
tions (Montgomery-Brown and Reinhard
2003; Ying et al. 2002). 4-Nonylphenol (NP)
is one of the most widely used and studied
APs [European Commission (EC) 2002a;
U.S. Environmental Protection Agency (EPA)
2003]. BPA and NP can be released into the
environment during the manufacturing
process and by leaching from the ﬁnal prod-
ucts (Guenther et al. 2002; Maguire 1999;
Staples et al. 1998). Because of the widespread
use of BPA and NP, the potential for human
exposure is high.
Toxicologic studies of laboratory animals
suggest that exposure to BPA and NP is asso-
ciated with morphologic, functional, and
behavioral anomalies related to reproduction.
NP is estrogenic in vitro and in vivo (Kwack
et al. 2002), interferes with the estrous cycle
and pubertal onset in rats (Kim et al. 2002;
Laws et al. 2000), and shows aquatic toxicity at
low (micrograms per liter) concentrations
(Hemmer et al. 2001; Ying et al. 2002).
Exposure of rodent fetuses to low BPA doses
of 20–400 µg/kg/day produces postnatal estro-
genic effects, including reduced daily sperm
production and increased prostate gland
weight in males, alteration in the development
and tissue organization of the mammary gland,
disruption of sexual differentiation in the
brain, long-term deleterious effects in the
vagina, and accelerated growth and puberty in
females (Howdeshell et al. 1999; Kubo et al.
2003; Markey et al. 2001; Nagel et al. 1997;
Schonfelder et al. 2002; vom Saal et al. 1998;
Welshons et al. 1998; White et al. 1994). In
mice treated with BPA at oral doses compa-
rable with environmental exposure levels
(20–100 µg/kg body weight/day), BPA
appears to be a potent disruptor of meiosis, the
cell division process that creates sperm or eggs,
leading to aneuploidy (Hunt et al. 2003).
Aneuploidy (an error in cell division) during
meiosis is thought to be the most common
known cause of mental retardation as well as
being the leading genetic cause of pregnancy
loss in humans (Hassold and Hunt 2001).
Data on human exposure to NP are scarce
(Inoue et al. 2003; Kawaguchi et al. 2004).
NP was measured in the urine samples of
10 healthy volunteers using column-switching
liquid chromatography/mass spectrometry
(Inoue et al. 2003). NP was detected at con-
centrations higher than the limit of detection
(LOD; 0.3 ng/mL) in one sample. Recently,
NP was measured in five urine and three
plasma samples from eight adult volunteers by
using stir-bar sorptive extraction-thermal des-
orption–gas chromatography/mass spectrome-
try (GC/MS) (Kawaguchi et al. 2004). The
NP concentrations in urine were below the
LOD (0.2 ng/mL).
The urinary BPA levels in various popula-
tions in Southeast Asia have been reported
(Arakawa et al. 2004; Matsumoto et al. 2003;
Ouchi and Watanabe 2002; Yang et al. 2003).
BPA was measured in morning spot urine
samples from two different groups of univer-
sity students in Japan in 1992 (n = 50, 92%
male) and 1999 (n = 56, 87.5% male). Most
BPA was found in the urine as the glucuronide
conjugate. The median urinary BPA levels in
1992 were approximately 2.2-fold higher than
in 1999 (Matsumoto et al. 2003). In another
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Bisphenol A (BPA) is used to manufacture polycarbonate plastic and epoxy resins, which are used
in baby bottles, as protective coatings on food containers, and for composites and sealants in den-
tistry. 4-Nonylphenol (NP) is used to make nonylphenol ethoxylates, nonionic surfactants applied
as emulsifying, wetting, dispersing, or stabilizing agents in industrial, agricultural, and domestic
consumer products. The potential for human exposure to BPA and NP is high because of their
widespread use. We measured BPA and NP in archived urine samples from a reference population
of 394 adults in the United States using isotope-dilution gas chromatography/mass spectrometry.
The concentration ranges of BPA and NP were similar to those observed in other human popula-
tions. BPA was detected in 95% of the samples examined at concentrations ≥ 0.1 µg/L urine; the
geometric mean and median concentrations were 1.33 µg/L (1.36 µg/g creatinine) and 1.28 µg/L
(1.32 µg/g creatinine), respectively; the 95th percentile concentration was 5.18 µg/L (7.95 µg/g
creatinine). NP was detected in 51% of the samples examined ≥ 0.1 µg/L. The median and 95th
percentile concentrations were < 0.1 µg/L and 1.57 µg/L (1.39 µg/g creatinine), respectively. The
frequent detection of BPA suggests widespread exposure to this compound in residents of the
United States. The lower frequency of detection of NP than of BPA could be explained by a lower
exposure of humans to NP, by different pharmacokinetic factors (i.e., absorption, distribution,
metabolism, elimination), by the fact that 4-n-nonylphenol—the measured NP isomer—represents
a small percentage of the NP used in commercial mixtures, or a combination of all of the above.
Additional research is needed to determine the best urinary biomarker(s) to assess exposure to NP.
Despite the sample population’s nonrepresentativeness of the U.S. population (although sample
weights were used to improve the extent to which the results represent the U.S. population) and
relatively small size, this study provides the ﬁrst reference range of human internal dose levels of
BPA and NP in a demographically diverse human population. Key words: bisphenol A, exposure,
human, NHANES III, nonylphenol, urine. Environ Health Perspect 113:391–395 (2005).
doi:10.1289/ehp.7534 available via http://dx.doi.org/ [Online 20 December 2004]
Research Articlestudy, BPA glucuronide was detected in all of
the urine samples collected from 48 female
Japanese college students at concentrations
ranging from 0.2 to 19.1 ng/mL, with a
median level of 1.2 µg/L (0.77 µg/g creati-
nine) (Ouchi and Watanabe 2002). The
largest BPA nonoccupational exposure assess-
ment reported urinary levels of BPA in a
group of 73 adult Koreans (53.4% female).
The geometric mean (GM) concentration of
BPA was 9.54 µg/L (8.91 µg/g creatinine)
(Yang et al. 2003). A recent study in Japan
reported a median daily urinary excretion of
BPA of 1.2 µg/day and a maximum daily
intake of BPA per body weight to be
0.23 µg/kg/day based on the measurement of
BPA in 24-hr urine samples collected from
36 men (Arakawa et al. 2004). This estimated
maximum daily intake was lower than the
temporary tolerable daily intake (10 µg/kg) set
by the European Commission’s Scientific
Committee in Food in 2002 (Arakawa et al.
2004; EC 2002b).
Occupational exposure to BPA has been
assessed in a cross-sectional study involving
84 male workers in plastic plants in Japan
(Hanaoka et al. 2002). Forty-two of the work-
ers used bisphenol A diglycidyl ether
(BADGE) and mixed organic solvents for
spraying epoxy resin hardening agents, whereas
the other 42 workers did not use BADGE.
The median concentrations of urinary BPA
were higher (p = 0.002) in the sprayers
(1.06 µmol/mol creatinine) than in the nonex-
posed workers (0.52 µmol/mol creatinine).
Similarly, the concentrations of urinary
metabolites of the organic solvents used were
signiﬁcantly higher in the sprayers than in the
nonexposed workers. In contrast, the median
plasma concentrations of follicle-stimulating
hormone (FSH) were lower (although within
the normal range) in the sprayers than in the
nonexposed workers (p = 0.022). The levels of
FSH were slightly negatively correlated with
those of BPA (correlation coefficient, –0.2,
p = 0.071) but not with the metabolites of the
organic solvents. On the basis of these results,
the authors postulated that BPA may disrupt
the secretion of gonadotropic hormones in
men, although they also acknowledged that the
clinical significance of these findings is still
unclear and should be further investigated
(Hanaoka et al. 2002).
Although no clear association has been
established between human exposure to BPA
or NP and adverse health effects, studies to
investigate the prevalence of exposure to these
environmental phenols are warranted because
of their potential harmful effects. Here we
report the levels of BPA and NP in urine
from a demographically diverse sample of
U.S. adults using a sensitive technique
(Kuklenyik et al. 2003) as a tool for assessing
the internal dose of these compounds.
Materials and Methods
The urine samples analyzed for this study were
selected from the Third National Health and
Nutrition Examination Survey (NHANES III)
callback cohort, a nonrepresentative subset of
NHANES III composed of approximately
1,000 adults. The urine samples were all spot-
urine samples, collected at different times
throughout the day and were not necessarily
ﬁrst-morning voids. Creatinine adjustment was
used to correct for urine dilution (Jackson
1966).
BPA and 4-n-nonylphenol (nNP), the
linear chain NP isomer, were measured
using a method based on an automated solid-
phase extraction (SPE) coupled to isotope
dilution-GC/MS (Kuklenyik et al. 2003).
First, the urine samples were treated with
β-glucuronidase to hydrolyze the glucuronide
conjugates. Then, during the automated SPE
process, BPA and nNP were both extracted
from the deconjugated urine matrix and
derivatized, using pentafluorobenzyl bro-
mide, on commercial styrene-divinylbenzene
copolymer-based SPE cartridges. After elu-
tion from the SPE column, the derivatized
phenols in the SPE eluate were measured by
isotope-dilution GC/MS. The limits of
detection (LODs) for BPA and nNP in a
1-mL urine sample were 0.1 µg/L.
Quality control (QC) materials were
analyzed along with the samples to assure
the accuracy and reliability of the data. Low-
concentration (QCL, 2–5 ng/mL) and high-
concentration (QCH, 12–20 ng/mL) QC
materials were prepared from a base urine
pool—obtained from multiple anonymous
donors as described previously (Kuklenyik
et al. 2003)—dispensed in 5-mL aliquots and
stored at –20°C. Each QC material was char-
acterized by repeated measurements, spanned
over at least 4 weeks, to deﬁne the mean con-
centrations and the 95% and 99% control
limits of BPA and nNP. Each analytical run
consisted of 40 (2 QCH, 2 QCL, 4 blanks,
and 32 unknown) samples. The concentra-
tions of the two QCH and the two QCL,
averaged to obtain one measurement of
QCH and QCL for each run, were evaluated
using standard statistical probability rules.
The samples used for this study were
stored securely at –70°C and may have been
subject to repeated thaw/freeze cycles. Before
analysis, the samples and QC materials were
left to thaw overnight at 5°C. The concentra-
tions of the analytes in the QCs remained
essentially constant under these experimental
conditions. Furthermore, QC materials reana-
lyzed after the initial characterization showed
that BPA and nNP remained stable in the
QC materials at –20°C for at least 1 year.
Although the long-term stability of the ana-
lytes in the urine samples stored for > 1 year is
not known, the QC data suggest that the
integrity of the specimens is likely maintained
and that chemical degradation of the phenols
was undetectable.
To estimate total sample size, we used a
standard formula n = t2p(1 – p)/d2, where n is
the estimated sample size, t is the critical value
associated with the desired statistical confi-
dence level, and d is the maximum allowable
error above or below the estimate of the true
proportion (p) of the target population with
measurable levels of the analyte(s) of interest
(Peavy 1996). Using a confidence level of
99% (t = 2.6), d = 0.065, and a 50% percent-
age of the population with measurable BPA
and nNP levels (p = 0.5), the estimated total
sample size was 400. Participants in this study
were 20–59 years of age, of both sexes, and
urban and rural residents. An arbitrary cutoff
of 100,000 inhabitants per county was used to
distinguish rural from urban areas. Each sam-
ple, deﬁned by age (< 50 years or ≥ 50 years),
residence (rural or urban), and sex (male or
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Table 1. GM and selected percentiles of BPA concentrations [µg/L (µg/g creatinine)] in urine.
Percentile
GM 10th 25th 50th 75th 90th 95th No. (%)a
Total 1.33 0.22 0.58 1.28 2.46 4.10 5.18 394 (95)
(1.36) (0.23) (0.70) (1.32) (2.58) (3.88) (7.95)
Age group (years)
< 50 1.43 0.44 0.84 1.87 3.13 5.15 7.51 317 (95)
(1.34) (0.44) (0.74) (1.53) (2.34) (3.77) (6.64)
≥ 50 0.99 0.18 0.51 1.23 2.32 4.00 4.83 77  (94)
(1.44) (0.15) (0.65) (1.29) (2.60) (3.88) (7.95)
Place of residence
Rural 1.44 0.38 0.69 1.28 2.35 3.79 4.76 153  (99)
(1.60) (0.36) (0.73) (1.37) (2.58) (3.83) (9.06)
Urban 1.27 0.18 0.41 1.27 2.58 4.42 6.26 241  (92)
(1.23) (< LOD) (0.53) (1.20) (2.60) (3.88) (7.95)
Sex
Male 1.63 0.40 0.71 1.30 2.36 4.42 8.02 184 (96)
(1.35) (0.15) (0.57) (1.20) (1.91) (3.05) (7.95)
Female 1.12 0.17 0.49 1.27 2.46 3.68 4.83 210 (94)
(1.35) (0.36) (0.72) (1.77) (2.95) (4.49) (9.06)
LOD is 0.1 µg/L. 
aNumber of subjects (percentage of detection).female), was categorized in eight subpopula-
tion groups (e.g., < 50-year-old rural female).
Because samples were obtained from the
NHANES III callback cohort, a nonrepresen-
tative subset of NHANES III samples, the
summary statistics are not representative of the
U.S. population but serve as reference ranges
for the three population breakdowns speciﬁed
above (i.e., persons < 50 or ≥ 50 years of age;
rural or urban residents; male or female). To
improve the extent to which the results repre-
sent the U.S. population, we used sample
weights. We developed our own weights for
demographic groups, not for individual sub-
jects. This approach is different from that
used by the National Center for Health
Statistics (NCHS) of the Centers for Disease
Control and Prevention (CDC). The NCHS
assigns a unique weight to each subject based
on demographics, geographical data, and
oversampling of certain population groups.
Because we only had information on age
group, sex, and residence (i.e., rural and
urban), we could not assign weights to indi-
vidual subjects, only to the demographic
groups. We determined the weights by relat-
ing the sample sizes in each of the eight
groups to the total numbers of persons in the
U.S. population in the same groups defined
by sex, residence, and age. From within these
eight groups, we randomly selected 394 sam-
ples. The institutional review board of the
NCHS approved the study.
We analyzed the weighted data using
SAS software, version 8.2 (SAS Institute,
Cary, NC). Because the base-10 logarithm
of the concentrations (log-transformed
concentrations) was less skewed than the
nontransformed values, we used the log-
transformed values in the analyses. We calcu-
lated GMs and distribution percentiles for
both volume-based (micrograms per liter)
and creatinine-corrected concentrations
(micrograms per gram creatinine). The GMs
were exponentiated results obtained from the
means of the log-transformed concentrations.
GMs were calculated when the frequency of
detection of the analyte was > 60%. We did
not use weights to obtain GM or percentile
estimates for the various demographic groups
because each subject in a demographic group
had the same weight.
For exploratory purposes only, we com-
pared BPA and NP levels among subgroups
(by age, sex, and place of residence) even
though we did not design the study to assure
adequate statistical power for this type of
hypothesis testing (i.e., the sample size was
determined to answer only the question about
the percentage of population with measurable
urinary BPA and/or NP levels). We used
weighted analysis of covariance models to
study the effects of residence, sex, age group,
and urinary creatinine on the urinary log-
transformed concentrations of BPA and NP.
The analyses were performed using SAS Proc
GENMOD (SAS Institute) to model the log-
transformed concentrations (dependent vari-
able) as a function of sex, residence, age group
(categorical covariates), and urinary creatinine
(continuous covariate used to adjust for urine
dilution). The purpose of our model adjust-
ment was not to apply an individual adjust-
ment to BPA and NP concentrations, but
rather to enable us to determine whether
there are differences in average BPA or NP
urinary levels between individuals in the same
demographic groups (e.g., men vs. women)
after accounting for the differences due to uri-
nary dilution. By adjusting for creatinine, we
obtained a comparison that was not influ-
enced by differences in creatinine levels. We
also considered all possible two-way inter-
actions between covariates. Type 3 equivalent
sums of squares from the model were used to
form likelihood ratio tests of model effects
and various tests of hypotheses. Statistical sig-
nificance was set at p < 0.05. We dealt with
results < LOD by using a multiple imputation
method (Lynn 2001) along with the SAS pro-
cedure PROC MIANALYZE, which summa-
rizes parameter estimates and incorporates the
resulting uncertainty associated with the mul-
tiple imputations used to obtain them.
Results
The distributions of BPA and NP in 394
NHANES III callback cohort urine samples
analyzed are shown in Table 1 and Figure 1,
respectively. For NP, results were available for
371 samples. Ninety-ﬁve percent of the sam-
ples measured had detectable concentrations
of BPA, suggesting that human exposure to
BPA is widespread. NP was detected in 51%
of the samples. The lower frequency of NP
than BPA detection could be because nNP
(the compound we measured) represents a
small percentage of the NP present in the NP
commercial mixtures, to relative differences in
the used amounts of BPA and NP ethoxylates
(the environmental precursors of NP), the
degree of human exposure, the pathways and
routes of exposure, pharmacokinetic factors
(i.e., absorption, distribution, metabolism,
and elimination), or a combination of all of
the above.
Beginning with the initial BPA model
described above, we arrived at a final model
that included residence, creatinine, and resi-
dence-by-creatinine interaction (Table 2). We
calculated adjusted GM estimates of BPA for
residence groups by using the mean values of
the continuous covariate (i.e., creatinine). For
BPA, the main effects for sex and age group
were not statistically signiﬁcant, and they were
excluded from the ﬁnal model. In contrast, the
residence × creatinine term was statistically sig-
niﬁcant (p = 0.0249), suggesting that the esti-
mated difference in BPA concentrations
between urban and rural residents depended
upon the urinary creatinine level, and that the
relationship between urinary levels of BPA and
creatinine is not the same for urban and rural
residents. The adjusted GM of BPA for an
urban resident (1.21 µg/L) was significantly
lower (p = 0.0014) than that for a rural resi-
dent (1.56 µg/L). These values (Table 2) com-
pared well with the observed values (Table 1).
According to the model results, BPA levels for
rural residents were expected to be 1.28 [95%
confidence interval (CI), 1.05–1.57] times
higher than those for urban residents assuming
a urinary creatinine concentration in both
groups of 12.63 mmol/L. Furthermore, on the
basis of model results, every mmol/L increase
in urinary creatinine levels was expected to be
associated with a 5.8% (95% CI, 0.4–8.1%)
increase in BPA levels for rural residents and a
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Figure 1. Ninety-fifth percentile concentration (in
µg/L and µg/g creatinine) of NP in a human refer-
ence population of 371 adults. The frequency of
detection of NP was 51%, and the median concen-
tration was < 0.1 µg/L. For each demographic sub-
group, the frequency of detection was 53%
(< 50 years of age), 45% (≥ 50 years of age), 51%
(rural resident), 51% (urban resident), 55% (male),
and 48% (female). The median concentrations of
NP were < 0.1 µg/L, except for males (0.17 µg/L),
urban residents (0.11 µg/L), and those < 50 years of
age (0.11 µg/L).
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Table 2. Multivariate modela considering the relation of measured BPAb to independent predictor variables.
Independent variable Speciﬁcation No. GMc p-Value
Residence Rural 153 1.56 0.0014
Urban 241 1.21
Creatinine Continuous 394 0.039d < 0.0001
Residence × creatinine Rural 153 –0.015d 0.0249
Urban 241
aEach variable was adjusted for the others in the model; r2 for the model is 0.26. bThe dependent variable is log10(BPA) for
model calculations (µg/L). cModel-calculated GM. dValues shown are β [i.e., slope from the multivariate analysis of the
regression of log10(BPA) versus the continuous independent variable]. 9.5% (95% CI, 7.2–11.9) increase for urban
residents. These data suggest the possibility of
variations in exposure to BPA on the basis of
place of residence. However, the nature of
these variations is not apparent (maybe due to
differences in diet, lifestyle, or exposure to
other chemicals) and is difﬁcult to explain with
the available demographic data.
For NP, no statistically significant inter-
actions existed between any of the covariates
considered, and none of the categorical main
effects was statistically significant. Only uri-
nary creatinine was statistically significant
(p < 0.0001). The slope (β) from the multi-
variate analysis of the regression of log10(NP)
versus creatinine was 0.036. On the basis of
model results, the NP GM concentration was
< LOD (0.1 µg/L), assuming all participants
had an average urinary creatinine of
12.63 mmol/L. Furthermore, for every milli-
mole per liter increase in urinary creatinine,
NP concentration increased by 8.6% (95%
CI, 5.6–11.7).
Because of the relatively large percentage
of NP results < LOD, we performed a logistic
regression analysis to determine whether any
of the covariates might be associated with an
NP level large enough to be detected. The
results of this analysis showed no evidence for
an effect of the categorical covariates (i.e., sex,
residence, age group) on the likelihood (i.e.,
probability) of a subject having a measurable
NP concentration. For every mmol/L increase
in creatinine concentrations, the likelihood of
a measurable NP level increased by 9.1%
(95% CI, 5.6–12.7), conﬁrming that the like-
lihood of measurable NP levels is associated
with increased urine concentration (using
creatinine as an indicator of urine concentra-
tion) that also is directly related to increased
NP concentrations. We found no signiﬁcant
correlation between the levels of urinary BPA
and NP (data not shown). These ﬁndings sug-
gest that, as expected, no common source of
exposure exists for BPA and NP.
Discussion
We measured BPA and NP in a group of 394
urine samples from the NHANES III callback
cohort (Table 1, Figure 1). NHANES III,
conducted from 1988 through 1994 by the
NCHS (1994), was designed as a nationally
representative survey. However, the environ-
mental component, known as the callback
cohort (~ 1,000 adults who agreed that addi-
tional blood and urine samples could be
taken), was not. Although each demographic
group had some representation in the call-
back cohort, no rigorous sample design and
no sample weights were used in analyzing the
resulting data. Furthermore, for this study,
we calculated the total sample size (~ 400) to
assure that we could estimate the true pro-
portion of the population with measurable
BPA and/or NP urinary concentrations
within 6.5 percentage points with 99% con-
fidence. It is likely that this sample size was
too small to detect significant differences
between the various subgroups defined by
age, residence, and sex. Even though our
population does not represent the composi-
tion of the general U.S. population and the
sample size is relatively small, our reported
values are from a diverse adult U.S. popula-
tion, a larger and broader population base
than those in previous studies (Arakawa et al.
2004; Matsumoto et al. 2003; Ouchi and
Watanabe 2002; Yang et al. 2003).
The median concentrations of BPA in the
NHANES III samples analyzed were similar
to the concentrations found in a group of
48 Japanese adults (Ouchi and Watanabe
2002), but the GM concentration of BPA was
about seven times lower than in a group of
73 adult Koreans (Yang et al. 2003). These
data suggest that differences in the exposure to
BPA may exist geographically. However,
because of the relatively small sample size of
these studies, the data should be interpreted
cautiously. The range of NP concentrations in
the NHANES III samples compared well with
previous data (Inoue et al. 2003; Kawaguchi
et al. 2004).
The relatively low NP concentrations and
lower frequency of detection compared with
that of BPA may result, at least in part, from
alternative metabolic pathways. Orally
administered BPA is rapidly metabolized to
its monoglucuronide in rats (Pottenger et al.
2000) and humans (Volkel et al. 2002) and
excreted in the urine. In six adult volunteers
administered orally with D16-BPA (5 mg),
D16-BPA was rapidly absorbed from the
gastrointestinal tract. The urinary excretion
and elimination from blood of D16-BPA glu-
curonide were very similar, with terminal half-
lives of 5.4 hr and 5.3 hr, respectively.
Furthermore, the applied dose of D16-BPA
was completely recovered in urine as D16-BPA
glucuronide approximately 24 hr after
administration (Volkel et al. 2002). In turn,
after oral application of 13C6-NP (5 mg) to a
human volunteer, Muller et al. (1998) showed
that only 10% of the dose was excreted in the
urine as NP within 8 hr and suggested the
occurrence of additional metabolites, which
could not be identified with their method.
Other studies have demonstrated that NP
undergoes metabolism in ﬁsh (Coldham et al.
1998; Thibaut et al. 1998, 1999) and rats
(Doerge et al. 2002; Green et al. 2003; Zalko
et al. 2003) resulting both in side chain- and
ring-hydroxylated NP metabolites. In Wistar
rats, a major percentage (~ 75%) of ring-2,6–
3H–nNP, administered by gavage, or oral
administered 14C6-nNP was excreted in urine
in the form of free, glucuronidated, or sul-
fated oxidative metabolites, primarily C1 and
C3 side-chain oxidative metabolites resulting
from ω- or β-oxidation of the NP C9 side
chain (Zalko et al. 2003). Several metabolites
were characterized by negative ion electrospray-
ion trap MS, namely, p-hydroxybenzoic acid,
3-(4-hydroxyphenyl)-2-propionic acid, 3-(4-
hydroxyphenyl)-2-propenoic acid, and a ring-
hydroxylated 3-(4-hydroxyphenyl)-2-propionic
acid. No nNP was detected in urine (Zalko
et al. 2003). In rainbow trout, after oral
ingestion of ring-2,6–3H–nNP, the major
urinary metabolites were tentatively identiﬁed
as oxidative metabolites (Thibaut et al. 1999).
In another study, the excretion in urine of
unchanged 14C6-nNP in CD rats after oral
administration of the radiolabeled NP was
estimated to be < 5% of the dose (Green et al.
2003). In Sprague-Dawley rats, after oral
administration of NP, containing 95% of
branched side-chain NP isomers, considerable
amounts of aromatic ring hydroxylated glu-
curonides were detected in serum and liver
based on MS fragmentation properties
(Doerge et al. 2002; Green et al. 2003; Zalko
et al. 2003).
If the oxidative metabolism of NP also
prevails in humans, the use of NP as the sole
urinary biomarker for comparing relative
exposures of NP to other environmental phe-
nols (e.g., BPA) in a given study may be mis-
leading because the metabolism of NP is more
complex and results in more metabolites, thus
decreasing the relative amounts of NP in the
urine. Although ingested BPA is completely
recovered in urine as BPA glucuronide within
approximately 24 hr after exposure (Volkel
et al. 2002), only 10% of the ingested NP is
excreted in the urine as NP or conjugated NP
(e.g., glucuronide) (Muller et al. 1998).
Furthermore, given the method of manufac-
turing NP, little of the linear chain NP (i.e.,
nNP) is produced (EC 2002a). Therefore,
nNP, the compound we actually measured in
this study, represented only a small percentage
of the NP present in the NP commercial mix-
tures. Unfortunately, the lack of authentic
standards and isotope-labeled standards of
branched NPs precluded their quantiﬁcation
(Kuklenyik et al. 2003). Studies are ongoing
in our laboratory to determine whether the
NP oxidative metabolites tentatively identiﬁed
in animal studies, including the metabolites of
branched alkyl chain NPs, can be used to
assess exposure to NP in humans.
In summary, despite the sample popula-
tion’s relatively small size and its nonrepresen-
tativeness of the U.S. population (although we
used sample weights to improve the extent to
which the results represent the U.S. popula-
tion), this study provides the first reference
range of human internal dose levels of BPA
and NP. The higher frequency of detection of
BPA than of NP in urine suggests that human
exposure to BPA is more prevalent. However,
Article | Calafat et al.
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NP may be relevant in humans and nNP—the
NP isomer measured in this study—represents
a small percentage of the NP used in commer-
cial mixtures, exposure to NP may be underes-
timated. Additional research to establish the
relevance of oxidative metabolism of NP in
humans and to identify the urinary metabo-
lites of NP commercial mixtures is warranted.
Furthermore, the frequent human exposure to
these compounds highlights the need for
future studies to measure BPA and NP in a
nationally representative sample of the U.S.
population.
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